Virium Pharma

Active

Private limited companyfounded 20206 yrs activeKraenepoelpad 10, 9880 Aalter, BelgiumKBO/BCE: BE 0754.431.851

The computed 12-month bankruptcy probability of Virium Pharma is 1.6% (moderate). The 2025 annual accounts show equity of €4k and a net result of €60. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 22% of 11323 sector peers (fiscal year 2025). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.

Watch Print / PDF

Checked score

Score 2025

46 / 100

Fair

The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability36▼-34

Solvency30▲+1

Growth32=

Track record100

Bankruptcy probability, 12 months

1.6% Moderate

0%0.5%1.5%4%10%≥ 25%

How do we compute the score and the probability?

Credit advice for your own amount and term

Signals

Seven signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Limited track record

This company has not been active as long as an established one and statistically fails somewhat more often.

KBO · incorporation date

Age against the risk zone

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 46

Relative position

BE, all sectors

reference

Sector 46

higher

← fewer bankruptcies more bankruptcies →

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 22% of 11323 sector peers (2025).

NBB · sector comparison

Position among 11323 sector peers

Solvency

better than 22%

← weakest strongest →

Growing equity

Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.

NBB · annual accounts 2025

Equity per financial year

22232425

2022 to 2025 · latest year €4k

Latest accounts filed on time

The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 02-01-2026, 29 days ahead of the deadline.

NBB · 4 filings

Deviation from the deadline

2025

29 d early

2024

34 d early

2023

2 d early

2022

on the day

← before the deadline after the deadline →

The next deadline is still running

The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

30-06-2026 close23-09-2026 today31-01-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, micro schema

Equity

€4k▲ 1.4%

2024 · €4k

2022: €27k 2023: €3k 2024: €4k

2022 → 2025

Total assets

€96k▼ 21.7%

2024 · €122k

2022: €130k 2023: €108k 2024: €122k

2022 → 2025

Net result

€60▼ 94.5%

2024 · €1k

2022: €2k 2023: €-23k 2024: €1k

2022 → 2025

Working capital

€-7k▲ 11.0%

2024 · €-8k

2022: €-1k 2023: €-18k 2024: €-8k

2022 → 2025

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line2022202320242025Trend

Equity€27k-€3k▼ 88.0%€4k▲ 34.0%€4k▲ 1.4%

Operating result€4k-€-23k€1k€66▼ 95.2%

Net result€2k-€-23k€1k€60▼ 94.5%

Turnover and EBIT margin not published: the micro schema does not require them.

Result per fiscal year

Operating resultNet result

The operating result falls in 2025; 2025 is 95% below 2024.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €96k

12.3%

87.7%

Fixed assets €12k▼ 6.8%

Current assets €84k▼ 23.4%

Equity and liabilities €96k

95.5%

Equity €4k▲ 1.4%

Debt €92k▼ 22.5%

The debt ratio falls from 96.5% to 95.5%. Equity is higher and debt is lower.

Key figures and ratios

2025 value · change against 2024

EBITDA

€925▼

2024 · €10k

Cash flow

€919▼

2024 · €9k

Solvency

4.5%▲

2024 · 3.5%

Current ratio

0.92▼

2024 · 0.93

Quick ratio

0.92▲

2024 · 0.91

Debt / equity

21.02▼

2024 · 27.51

ROE

1.4%▼

2024 · 25.4%

ROA

0.1%▼

2024 · 0.9%

Interest coverage

2.10▼

2024 · 177.30

Debt

€92k▼

2024 · €118k

Debt ≤ 1 year

€92k▼

2024 · €118k

Income taxes

€256▲

2024 · €235

Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.

Filed annual accounts

As filed with the NBB · 2025 against 2024

Balance sheet Code20242025

Assets

Total assets20/58€122k€96k▼

Fixed assets21/28€13k€12k▼

Intangible fixed assets21€1k€497▼

Tangible fixed assets22/27€12k€11k▼

Furniture and vehicles24€12k€11k▼

Current assets29/58€110k€84k▼

Stocks and contracts in progress3€3k-

Stocks30/36€3k-

Amounts receivable within one year40/41€9k€16k▲

Trade receivables40€9k€15k▲

Other amounts receivable41€765€744▼

Cash at bank and in hand54/58€97k€68k▼

Deferred charges and accrued income490/1€308€326▲

Equity and liabilities

Total equity and liabilities10/49€122k€96k▼

Equity10/15€4k€4k▲

Contributions10/11€25k€25k=

Profit (loss) carried forward14€-21k€-21k▲

Amounts payable17/49€118k€92k▼

Amounts payable within one year42/48€118k€92k▼

Trade debts44€14k€1k▼

Suppliers440/4€14k€1k▼

Taxes, remuneration and social security45€3k€2k▼

Taxes450/3€1k€379▼

Remuneration and social security454/9€2k€2k=

Other amounts payable47/48€101k€88k▼

Income statement Code20242025

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€8k€859▼

Other operating charges640/8€1k€1k▼

Gross operating margin9900€11k€2k▼

Operating profit (loss)9901€1k€66▼

Financial income75/76B-€690

Recurring financial income75-€690

Financial charges65/66B€54€440▲

Recurring financial charges65€54€440▲

Profit (loss) for the period before taxes9903€1k€316▼

Income taxes67/77€235€256▲

Profit (loss) for the period9904€1k€60▼

Profit (loss) for the period to be appropriated9905€1k€60▼

Appropriation of the result

Profit (loss) to be appropriated9906€-21k€-21k▲

Profit (loss) brought forward from the previous period14P€-22k€-21k▲

The notes to these accounts (7 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 6Financial 2Filings 4

Next filing, fiscal year 2026, expected by 31-01-2027

2026

02-01

NBB filing Annual accounts filed

fiscal year 2025 · micro schema

2024

28-12

NBB filing Annual accounts filed

fiscal year 2024 · micro schema

30-06

Financial Back to profitnet €1k

Net result €1k after one loss-making year.

29-01

NBB filing Annual accounts filed

fiscal year 2023 · micro schema

2023

30-06

Financial Weakest financial yearnet €-23k ▼1488%

Net result drops to €-23k, the lowest in the series; recovery starts the following year.

31-01

NBB filing Annual accounts filed

fiscal year 2022 · micro schema

Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.

Location & real-estate footprint

Registered office, Aalter · 1 establishment unit since 2020

establishment The establishment unit on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Kraenepoelpad 109880 Aalter

Ground area

3,240 m²

Building footprint

517 m²

Volume, LiDAR

2,478 m³

Parcel 44502C0804/02G000, Flanders · tallest building 22.7 m, ±2 floors. Linked by address, not a title deed.

1 establishment unit

Virium Pharma

Kraenepoelpad 10, 9880 AalterManufacture of basic pharmaceutical products and pharmaceutical preparations

since 20202.307.284.065

1 parcel

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
44502C0804/02G000	Flanders	3,240 m²	1 · 516 m²	22.7 m · 2 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Public money · subsidies and aid

Flemish government

2022 to 2023 · 2 entries · 1,234 EUR awarded · 1,234 EUR paid

Year	Entries	awarded	paid
2023	1	56 EUR	1,166 EUR
2022	1	1,178 EUR	68 EUR

Schemes

Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)

2 entries · 1,234 EUR · 1,234 EUR paid · Fonds voor Innoveren en Ondernemen

Recognitions · licences · registrations

Food safety, FASFC

1 site

Aalter2.307.284.065

1 permission

Detailhandel LM>3 maand · since 15-09-2020

Similar companies · same sector, comparable size

Of 1,745 companies in sector 46150 we hold annual accounts for 757. 265 are within a factor 10 of this equity.See the whole sector

Company data · Crossroads Bank

Identification

Legal formPrivate limited company

Founded15-09-2020

Fiscal year end30-06

Activities, NACEBEL

46150Agents in the wholesale of furniture, household goods and hardware

21201Manufacture of basic pharmaceutical products and pharmaceutical preparations

21209Manufacture of basic pharmaceutical products and pharmaceutical preparations

47740Retail trade

47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses

47750Retail sale of cosmetics and toilet articles

64200Holdings

64210Activities of holding companies

70200Business and other management consultancy

70220Business consulting

72109Other research and development on natural sciences

Sources

Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers

Data from official sources, last processed on 23-09-2026. Scores and ratios are computed by Checked and are not a credit decision.